HEERLEN, Netherlands, May 3, 2022 /PRNewswire/ --
Highlights1
- DSM delivered a good first quarter
- Group sales +18% and Adjusted EBITDA +10%
- Health, Nutrition & Bioscience: Sales +16%, organic sales +9%, Adjusted EBITDA +9%
- Materials: Sales +25%, organic sales +21%, Adjusted EBITDA +11%
- Full Year outlook 2022 unchanged
Key figures 2
in € million |
Q1 2022 |
Q1 2021 |
% Change |
Volume |
Price/mix |
FX |
Other |
Sales |
2,590 |
2,194 |
18% |
2% |
10% |
5% |
1% |
HNB |
1,987 |
1,711 |
16% |
3% |
6% |
5% |
2% |
ANH |
881 |
778 |
13% |
-3% |
11% |
5% |
0% |
HNC |
726 |
625 |
16% |
8% |
3% |
5% |
0% |
F&B |
362 |
296 |
22% |
7% |
3% |
3% |
9% |
Materials |
582 |
467 |
25% |
-4% |
25% |
4% |
0% |
Adjusted EBITDA |
487 |
441 |
10% |
||||
HNB |
391 |
359 |
9% |
||||
Materials |
120 |
108 |
11% |
||||
Corporate |
-24 |
-26 |
|||||
EBITDA |
466 |
425 |
|||||
Adjusted EBITDA margin |
18.8% |
20.1% |
Co-CEOs statement
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: "DSM had a good start to the year with robust demand across our businesses and effective pricing measures to counteract inflation throughout the value chain. Despite the ongoing global logistics and supply chain challenges, the excellence of our people and our operations ensured we were able to continue to satisfy our customers' needs. While we see ongoing volatility, resilient demand for our innovative and sustainability-focused solutions, together with our ability to drive effective pricing, leads us to reiterate our full year outlook."
Outlook 2022
DSM's outlook for the full year is unchanged. DSM expects its Health, Nutrition & Bioscience activities to deliver a high-single digit Adjusted EBITDA increase. For the Group, it expects a mid-single digit Adjusted EBITDA increase, with a high-single Adjusted Net Operating Free Cash Flow increase. This outlook is based on DSM's expectation of a stable Adjusted EBITDA in Materials following the strong performance in 2021.
1 Adjusted EBITDA is an Alternative Performance Measure (APM) that reflects results from usual operations. Organic sales growth is the total impact of volume and price/mix. Adjusted Net Operating Free Cash Flow is the cash flow from operating activities, corrected for the cash flow of the APM adjustments, minus the cash flow of capital expenditures and drawing rights.
2 DSM's Health, Nutrition & Bioscience structure became effective as of 1 January 2022. It consists of three businesses: Animal Nutrition and Health (ANH), Health, Nutrition and Care (HNC) and Food & Beverage (F&B). The preliminary comparative financial figures for 2021 were released in April 2022.
Note for editors: For the full text of the press release, see the enclosed pdf or click here.
Financial calendar
10 May 2022 |
Annual General Meeting of Shareholders |
2 August 2022 |
Publication of the half year results of 2022 |
6 September 2022 |
Investor Day |
1 November 2022 |
Publication of the trading update first nine months of 2022 |
Contact information
DSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com |
DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 |
DSM
Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
Or find us on:
Facebook: http://www.facebook.com/DSMcompany
Twitter: http://www.twitter.com/DSM
LinkedIn: http://www.linkedin.com/company/3108
YouTube: http://www.youtube.com/user/dsmcompany
Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpg
The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.
